Patents Assigned to APROFOL AG
-
Publication number: 20230416253Abstract: The invention relates to crystalline folate salts. The salt consists of a folate anion and an organic cation. The folate anion is 5-methyl-(6S)-tetrahydrofolic acid, and the cation is an organic compound which is an alkanolamine selected from the group consisting of choline, N-methylaminoethanol, 2-amino-2-methylpropanol and 2-dimethylaminoethanol.Type: ApplicationFiled: September 8, 2023Publication date: December 28, 2023Applicant: APROFOL AGInventors: Martin Ulmann, Gerd Wiesler, Arthur Bodenmüller, Markus Müller
-
Patent number: 11787808Abstract: The invention relates to crystalline folate salts. The salt consists of a folate anion and an organic cation. The folate anion is 5-methyl-(6S)-tetrahydrofolic acid, and the cation is an organic compound which is an alkanolamine selected from the group consisting of choline, N-methylaminoethanol, 2-amino-2-methylpropanol and 2-dimethylaminoethanol.Type: GrantFiled: October 31, 2019Date of Patent: October 17, 2023Assignee: APROFOL AGInventors: Martin Ulmann, Gerd Wiesler, Arthur Bodenmüller, Markus Müller
-
Publication number: 20230158029Abstract: A composition is described comprising at least one folate which is useful in the treatment of ocular diseases linked to elevated retinal venous pressure.Type: ApplicationFiled: February 26, 2021Publication date: May 25, 2023Applicant: APROFOL AGInventors: Martin Ulmann, Gerd Wiesler, Josef Flammer
-
Publication number: 20210403471Abstract: The invention relates to crystalline folate salts. The salt consists of a folate anion and an organic cation. The folate anion is 5-methyl-(6S)-tetrahydrofolic acid, and the cation is an organic compound which is an alkanolamine selected from the group consisting of choline, N-methylaminoethanol, 2-amino-2-methylpropanol and 2-dimethylaminoethanol.Type: ApplicationFiled: October 31, 2019Publication date: December 30, 2021Applicant: APROFOL AGInventors: Martin Ulmann, Gerd Wiesler, Arthur Bodenmüller, Markus Müller (deceased)
-
Publication number: 20210308139Abstract: Preparations of folate for use in the treatment of eye disorders in the presence of elevated intraocular pressure. Methods of reducing intraocular pressure in a patient having an eye disease.Type: ApplicationFiled: August 29, 2019Publication date: October 7, 2021Applicant: APROFOL AGInventors: Martin Ulmann, Gerd Wiesler, Josef Flammer
-
Patent number: 9642853Abstract: The administration of leucovorin as well as other active, reduced folates is useful as an antidote to drugs which act as folic acid antagonists and in combination chemotherapy with 5-FU. The most often used calcium salts of the folates have a low solubility in water and form almost insoluble degradation products. Therefore, aqueous solutions are unstable and precipitates result. Precipitates in injectable products present an unacceptable safety risk to patients. Stable high strength pharmaceutical aqueous compositions are formed containing calcium salts, magnesium or zinc salts of the reduced folates leucovorin, (6R,S)-tetrahydrofolic acid, (6S)-tetrahydrofolic acid, 5,10-methylene-(6R,S)-tetrahydrofolate, 5,10-methylene-(6R)-tetrahydrofolate, 5-methyl-(6R,S)-tetrahydrofolate or 5-methyl-(6S)-tetrahydrofolate and one or more of the compounds sodium gluconate, potassium gluconate, glycerophosphate disodium salt or glycerophosphate dipotassium salt.Type: GrantFiled: April 30, 2014Date of Patent: May 9, 2017Assignee: APROFOL AGInventor: Martin Ulmann
-
Patent number: 9301922Abstract: The administration of levoleucovorin is useful as an antidote to drugs which act as folic acid antagonists and in combination chemotherapy with 5-FU. The most often used calcium salt of levoleucovorin has a limited solubility in water and forms almost insoluble degradation products. Therefore aqueous solutions are unstable and precipitates are resulting. Precipitates in injectable products present an unacceptable safety risk to patients. Stable high strength pharmaceutical aqueous compositions containing calcium salts, magnesium or zinc salts of levoleucovorin and one or more of the compounds sodium gluconate, potassium gluconate, glycerophosphate disodium salt or glycerophosphate dipotassium salt are disclosed.Type: GrantFiled: April 30, 2014Date of Patent: April 5, 2016Assignee: APROFOL AGInventor: Martin Ulmann
-
Publication number: 20160081926Abstract: The administration of levoleucovorin is useful as an antidote to drugs which act as folic acid antagonists and in combination chemotherapy with 5-FU. The most often used calcium salt of levoleucovorin has a limited solubility in water and forms almost insoluble degradation products. Therefore aqueous solutions are unstable and precipitates are resulting. Precipitates in injectable products present an unacceptable safety risk to patients. Stable high strength pharmaceutical aqueous compositions containing calcium salts, magnesium or zinc salts of levoleucovorin and one or more of the compounds sodium gluconate, potassium gluconate, glycerophosphate disodium salt or glycerophosphate dipotassium salt are disclosed.Type: ApplicationFiled: April 30, 2014Publication date: March 24, 2016Applicant: APROFOL AGInventor: Martin ULMANN
-
Publication number: 20160074402Abstract: The administration of leucovorin as well as other active, reduced folates is useful as an antidote to drugs which act as folic acid antagonists and in combination chemotherapy with 5-FU. The most often used calcium salts of the folates have a low solubility in water and form almost insoluble degradation products. Therefore, aqueous solutions are unstable and precipitates result. Precipitates in injectable products present an unacceptable safety risk to patients. Stable high strength pharmaceutical aqueous compositions are formed containing calcium salts, magnesium or zinc salts of the reduced folates leucovorin, (6R,S)-tetrahydrofolic acid, (6S)-tetrahydrofolic acid, 5,10-methylene-(6R,S)-tetrahydrofolate, 5,10-methylene-(6R)-tetrahydrofolate, 5-methyl-(6R,S)-tetrahydrofolate or 5-methyl-(6S)-tetrahydrofolate and one or more of the compounds sodium gluconate, potassium gluconate, glycerophosphate disodium salt or glycerophosphate dipotassium salt.Type: ApplicationFiled: April 30, 2014Publication date: March 17, 2016Applicant: APROFOL AGInventor: Martin ULMANN